View Exam | PowerPak

1. After participating in this activity, how often do you NOW INTEND TO implement pharmacists-driven monitoring strategies for your patients requiring treatment with immunotherapy?

A. Rarely B. Sometimes C. Often D. Always

2. After participating in this activity, how confident are you NOW regarding your ability to appropriately manage potential treatment-related adverse events in your patients requiring immunotherapy for non-small cell lung cancer or melanoma?

A. Not confident B. Somewhat confident C. Moderately confident D. Very confident

3. SR is a 50-year-old woman with newly diagnosed metastatic melanoma. Biopsy results reveal BRAF is wildtype. Which of the following are you MOST likely to recommend for SR?

A. Vemurafenib monotherapy B. Vemurafenib and cobimetinib combination therapy C. Dacarbazine D. Pembrolizumab

4. Which of the following adverse events is LEAST likely to be seen in a patient receiving ipilimumab therapy?

A. Mucositis B. Pruritus, rash C. Diarrhea D. Colitis

5. TG is a 57-year-old woman with metastatic non-small cell lung cancer who began therapy with nivolumab. After 10 weeks of therapy, she has developed severe (grade 3) diarrhea. Which of the following treatment strategies would you recommend next for TG?

A. Discontinue her treatment B. Hold therapy and initiate steroid therapy C. Hold therapy and initiate loperamide D. Continue nivolumab and initiate loperamide

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. After participating in this activity, how often do you NOW INTEND TO implement pharmacists-driven monitoring strategies for your patients requiring treatment with immunotherapy?

2. After participating in this activity, how confident are you NOW regarding your ability to appropriately manage potential treatment-related adverse events in your patients requiring immunotherapy for non-small cell lung cancer or melanoma?

3. SR is a 50-year-old woman with newly diagnosed metastatic melanoma. Biopsy results reveal BRAF is wildtype. Which of the following are you MOST likely to recommend for SR?

4. Which of the following adverse events is LEAST likely to be seen in a patient receiving ipilimumab therapy?

5. TG is a 57-year-old woman with metastatic non-small cell lung cancer who began therapy with nivolumab. After 10 weeks of therapy, she has developed severe (grade 3) diarrhea. Which of the following treatment strategies would you recommend next for TG?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. After participating in this activity, how often do you NOW INTEND TO implement pharmacists-driven monitoring strategies for your patients requiring treatment with immunotherapy?

2. After participating in this activity, how confident are you NOW regarding your ability to appropriately manage potential treatment-related adverse events in your patients requiring immunotherapy for non-small cell lung cancer or melanoma?

3. SR is a 50-year-old woman with newly diagnosed metastatic melanoma. Biopsy results reveal BRAF is wildtype. Which of the following are you MOST likely to recommend for SR?

4. Which of the following adverse events is LEAST likely to be seen in a patient receiving ipilimumab therapy?

5. TG is a 57-year-old woman with metastatic non-small cell lung cancer who began therapy with nivolumab. After 10 weeks of therapy, she has developed severe (grade 3) diarrhea. Which of the following treatment strategies would you recommend next for TG?

« Return to Activity

Customers who Purchased
this Activity also Purchased